Endoscopic Lung Volume Reduction: An Expert Panel Recommendation – Update 2019

Endoscopic lung volume reduction (ELVR) therapies are gaining prominence as a treatment option with guideline recommendations by COPD GOLD and NICE and the recent FDA approval for endobronchial valves. The transition from an experiment-based therapy only to clinical care comes with new challenges. A...

Full description

Saved in:
Bibliographic Details
Published inRespiration Vol. 97; no. 6; pp. 548 - 557
Main Authors Herth, Felix J.F., Slebos, Dirk-Jan, Criner, Gerard J., Valipour, Arschang, Sciurba, Frank, Shah, Pallav L.
Format Journal Article
LanguageEnglish
Published Basel, Switzerland 01.01.2019
Subjects
Online AccessGet full text
ISSN0025-7931
1423-0356
1423-0356
DOI10.1159/000496122

Cover

More Information
Summary:Endoscopic lung volume reduction (ELVR) therapies are gaining prominence as a treatment option with guideline recommendations by COPD GOLD and NICE and the recent FDA approval for endobronchial valves. The transition from an experiment-based therapy only to clinical care comes with new challenges. A significant volume of evidence-based data has been published; all data demonstrate consistent improvements in several aspects of patient outcomes. Patients suffering from severe air trapping and thoracic hyperinflation seem to benefit the most from ELVR. In addition to lung function, baseline assessment should ideally include cardiopulmonary exercise testing, high-resolution computer tomography scan, perfusion scintigraphy, and echocardiography. This expert ELVR statement updates best practice recommendations from 2017 regarding patient selection and utilization of these various techniques for treating patients with advanced emphysema.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0025-7931
1423-0356
1423-0356
DOI:10.1159/000496122